Business context and reporting period
Aytu BioScience, Inc. is a commercial-stage specialty healthcare company focused on urology. This Form 10-Q covers the quarter and nine months ended March 31, 2016 (fiscal 2016 third quarter), not 2015 Q3 as stated in the request metadata. The company was expanding commercialization of ProstaScint and Primsol and developing diagnostic products; it also announced a Natesto U.S. licensing deal after quarter-end. The prior-year periods predate key acquisitions and the April 2015 merger, limiting comparability.
Financial performance and liquidity
- Revenue: Quarterly revenue was $668,541, versus $23,829; nine-month revenue was $1.625 million, versus $79,746. Nine-month product and service revenue was $1.561 million, offset by $532,000 of sales deductions from gross product revenue of $2.093 million. License revenue was $64,286.
- Profit and margins: Net loss was $7.274 million for the quarter, versus $1.842 million, and $12.883 million for nine months, versus $5.568 million. Nine-month operating loss was $8.404 million. Cost of sales was $622,222 for nine months; the filing does not present a consolidated gross-margin measure.
- Expenses and unusual items: Nine-month R&D was $3.308 million and SG&A was $5.671 million. Interest expense was $4.428 million for nine months, driven substantially by noncash amortization of the convertible notes’ beneficial conversion feature; the cash-flow statement reports $3.943 million of that amortization.
- Cash flow: Nine-month operating cash use was $7.993 million; investing cash use was $742,000; financing provided $10.047 million. Cash increased $1.313 million to $8.666 million.
- Balance sheet: At March 31, cash was $8.666 million, current assets $10.437 million, current liabilities $3.205 million, total liabilities $4.420 million, and stockholders’ equity $17.566 million. The current ratio was approximately 3.3. Primsol payable was $1.155 million. Convertible notes had $1.050 million of remaining principal and $66,000 interest payable, although the balance-sheet carrying value of the notes was only $9,797 after discounts.
Changes versus prior comparable periods
- Revenue rose sharply from a very small base, reflecting product sales following acquisitions; cost of sales also began to be reported.
- Quarterly and nine-month losses widened as operating costs increased and the company recorded substantial convertible-note interest expense. Nine-month R&D increased 34% and SG&A increased 93%, primarily reflecting clinical/manufacturing work, staffing, and commercialization costs.
- Cash from operations increased to $8.0 million used, from $4.8 million used in the prior-year nine-month period. Financing inflows supported the cash balance; common shares outstanding rose to 22.446 million at March 31 from 14.260 million at June 30, 2015.
Outlook, risks, and subsequent events
- Management estimated operating cash needs of about $2 million per quarter, said available resources after the May offering should fund operations into the second half of fiscal 2017, and also said additional capital would be needed within 12 months. Financing availability on acceptable terms was uncertain.
- The May 2016 offering generated approximately $6.7 million net proceeds. The remaining $1.050 million note principal and $78,000 accrued interest converted on May 5 into 3,659,978 common shares and warrants. As of May 6, shares outstanding were 44,856,459, with 30,279,665 warrants and options.
- After quarter-end, Aytu licensed exclusive U.S. Natesto rights, paid a $2 million upfront fee, agreed to further upfront payments of $2 million in September 2016 and $4 million in January 2017, and bought approximately $2 million of Acerus shares. Additional sales-based milestone payments could total up to $37.5 million. The filing also describes significant supply, commercialization, and regulatory obligations.
- Management reported no material pending legal proceedings, effective disclosure controls, and no material changes in internal control. Key risks include continued reliance on external financing, Natesto commercialization and testosterone-therapy safety concerns, controlled-substance regulation, the Acerus investment, and OTCQX minimum-price compliance. Management said it was not pursuing U.S. clinical testing of Zertane and was considering strategic alternatives.
Important facts to verify
- Confirm the reporting-period discrepancy: the filing is for the quarter ended March 31, 2016, not 2015 Q3.
- Reconcile the $4.428 million nine-month interest expense to the noncash note discounts and beneficial conversion feature, and distinguish note face value from its balance-sheet carrying amount.
- Review post-quarter financing dilution, warrant terms, Natesto cash commitments, and the assumptions behind management’s runway estimate.
- Assess product sales deductions, customer demand, gross profitability, and the costs and timing of ProstaScint manufacturing and Natesto commercialization.
- Check subsequent developments in the OTCQX price-compliance matter, board independence, and any required Natesto safety studies.